Q3 makes a recovery from Q220 losses but gains remain below pre-COVID levels
For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention-Vascular Access Adjunct Products market was down -1.8% YoY. Leading manufacturers in this segment hit hard in Q220 by COVID-19 restrictions and elective procedure cancellations reported positive growth over Q2, but are still not at pre-COVID-19 levels.
Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Infection Prevention: US Vascular Access Adjunct Market Recap* are:
- Complete Q320 Infection Prevention Market Highlights
- Dressings: Securement and Stabilization of VA Devices
- Antimicrobial Devices
- Antimicrobial IV Skin Preps
- Mechanical Securement Devices
- Q320 Regulatory Highlights and News of Interest
The COVID-19 crisis continues to put the spotlight on infection control within hospitals and further reinforces the importance of the infection preventionist (IP) in the “new normal” healthcare setting. Non-compliance with INS SOP and modifications of hospital procedures during the peak of the COVID-19 crises is expected to increase CRBSIs. Numerous modifications taking place during COVID-19 such as ...
*The entire article, including revenue, shares and links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution that networks an entire organization with real-time market data and analysis. Used by the 15 top Advanced Wound Care companies and 8 of the 10 top Orthopedic companies, SmartTRAK transforms the delivery of healthcare business information into a cost-effective solution for life science corporations to increase proficiency, improve productivity and reduce cost.
